article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

2005: HRSA publicly raised alarms against discriminatory reimbursement to 340B providers. There was bipartisan support for the program at the hearing and support for measures such as requiring pharmaceutical companies to publish their prices in a password protected site on HRSA's website.

article thumbnail

Ep. 001 – John Mack Podcast Transcript

Pharma Marketing Network

John Mack (PG): So, when I got laid off and as a consultant, I was working for a consulting company, helping them do websites for pharmaceutical companies in the.com bust, you know, a lot of people got laid off. It wasn’t just pharmaceutical companies and others. So that was 2005. It’s a blog.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CMC Requirements for New Drug Registration in Latin America

ISPE

In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceutical companies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements. Published 19 January 2005. Published November 2005.

article thumbnail

A New Regulatory Approach to Drive Sustainable Medicines

ISPE

A pharmaceutical quality system (PQS) is a management system used to direct and control a pharmaceutical company with regard to quality. link] 12 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Published November 2005. Pharmaceutical Engineering 42, no.